Our team aims to foster innovation and improve
the lives of people with kidney disease through…
Person-centered care shifts the focus from the disease to the whole person to enhance care experiences, promote patient activation, and improve outcomes. Our team facilitates integration of this philosophy into routine care through development, implementation, and evaluation of patient-reported outcome measures (PROMs), as well as ascertainment of patient preferences, priorities, and values.
- Clinical Trial: Comparative Effectiveness of an Individualized Model of Hemodialysis vs. Conventional Hemodialysis (TWOPLUS)
- Patient Priorities: Goal-Directed Dialysis Care
- Patient-Reported Outcome Measure (PROM) Clinical Trial: Dialysis-Related Symptoms
- Kidney Health Initiative Workgroup: Integrating Patient Preferences into Regulatory Decision Making
- Kidney Health Initiative Workgroup: Prioritizing Symptoms of Patients Receiving Dialysis
- Kidney Health Initiative Workgroup: Understanding Patient Preferences Workshop
- Dialysis Stakeholder Workshop: Cultivating a Research-Ready Dialysis Community
- CMS Technical Expert Panel: Dialysis Patient-Reported Outcomes (Panel Members and Summary Report)
Sub-optimal volume and blood pressure management contribute to high rates of hospitalization and death among individuals receiving hemodialysis. We conduct observational and prospective studies to identify strategies to improve volume-related outcomes and related patient experiences.
- Clinical Trial: Pilot Study of Loop Diuretics among Individuals Receiving Hemodialysis
- Clinical Trial: Ultrafiltration Profiling and Outcomes among Individuals on Maintenance Hemodialysis
- International Workshop: KDIGO Controversies Conference on Blood Pressure and Volume in Dialysis
- Kidney Health Initiative Workgroup: Fostering Innovation in Fluid Management
- Interviews: Fluid Removal During Hemodialysis (view Part One and Part Two)
- Calculator: Ultrafiltration Rate Calculator
Medications shown to be effective in the general population are often used for identical clinical indications in people receiving dialysis without an assurance of safety. We conduct large-scale, pharmacoepidemiologic studies to characterize the safety profiles of medications commonly prescribed to dialysis patients.
- Serum-to-dialysate potassium gradient modifies the cardiac safety of QT-prolonging antibiotics in dialysis patients
- Diuretic use among hemodialysis patients
- Antihyperglycemic medication use among hemodialysis patients
- Serum-to-dialysate potassium gradient modifies the cardiac safety of SSRIs in hemodialysis patients
- Azithromycin increases the risk of sudden cardiac death in hemodialysis patients
- PPIs enhance the risk of citalopram- and escitalopram-associated sudden cardiac death in hemodialysis patients
- Hemodialysis patients treated with respiratory fluoroquinolones (vs. amoxicillin) have a higher risk of sudden cardiac death
- Hemodialysis Patients Treated with Zolpidem (vs. Trazadone) Have a Higher Risk of Fall-Related Fractures
- Studies Provide Comparative Data on Antidepressant Safety and Efficacy
- Hemodialysis Patients May Benefit by Staying on Loop Diuretics
- In Dialysis Patients, Mortality Differs between Beta-Blockers
Health education is an essential tool for promoting patient engagement, activation, and self-efficacy. We aim to improve research processes and clinical care by partnering with stakeholders to create mixed media materials (video and written) that inform individuals of health care options, research methods, and other identified knowledge gaps.